Flag of the European Union EU Clinical Trials Register Help

Clinical trials for No Smoking Day

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    553 result(s) found for: No Smoking Day. Displaying page 28 of 28.
    «« First « Previous 20  21  22  23  24  25  26  27  28 
    EudraCT Number: 2010-018431-18 Sponsor Protocol Number: REMICADECRD3001 Start Date*: 2010-08-23
    Sponsor Name:Janssen Biologics B.V.
    Full Title: Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE® (infliximab) and Placebo in the Prevention of Recurrence in Crohn’s Disease Patients Undergoing Surg...
    Medical condition: Crohn’s disease (CD)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed) FR (Completed) BE (Completed) NL (Completed) IT (Completed) HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2010-022721-14 Sponsor Protocol Number: QVA149A2305 Start Date*: 2011-02-07
    Sponsor Name:Novartis Farmaceutica, S.A.
    Full Title: Estudio multicéntrico, aleatorizado, ciego, doble simulación, con control placebo, tres periodos, cruzado, para evaluar el efecto del QVA149 (110/50 µg o.d.) en la resistencia al ejercicio en pacie...
    Medical condition: Enfermedad Pulmonar Obstructiva Crónica (EPOC)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-013504-32 Sponsor Protocol Number: CNVA237A2304 Start Date*: 2009-10-20
    Sponsor Name:Novartis Farmaceutica, S.A.
    Full Title: Estudio aleatorizado, doble ciego, de grupos paralelos, controlado con placebo para valorar la eficacia, seguridad y tolerabilidad durante un tratamiento de 26 semanas con NVA237 en pacientes con ...
    Medical condition: Enfermedad Pulmonar Obstructiva Crónica (EPOC)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10010952 COPD LLT
    9 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001324-19 Sponsor Protocol Number: BDS_18_01 Start Date*: 2018-08-02
    Sponsor Name:Marinomed Biotech AG
    Full Title: Demonstration of therapeutic equivalence/non-inferiority as well as early onset of action of the novel water-soluble budesonide nasal spray (Budesolv) compared with marketed Rhinocort® aqua 64 in p...
    Medical condition: Allergic Rhinitis/ Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10021428 - Immune system disorders 10019170 Hay fever LLT
    20.1 10021428 - Immune system disorders 10048908 Seasonal allergy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010714-30 Sponsor Protocol Number: 1275148SCD2001 Start Date*: 2009-10-23
    Sponsor Name:Janssen Biologics B.V.
    Full Title: A Phase 2, Multicenter, Randomized, Double blind, Parallel group, Placebo controlled Study Evaluating the Safety and Efficacy of Treatment with Ustekinumab or Golimumab in Subjects with Chronic Sar...
    Medical condition: Chronic sarcoidosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039486 Sarcoidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) GB (Completed) DK (Completed) FR (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002616-96 Sponsor Protocol Number: D3561C00087 Start Date*: 2006-08-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIIb, efficacy, and safety study of rosuvastatin in children and adolescents 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH): a 12-week, double-blind, randomiz...
    Medical condition: Heterozygous familial hypercholesterolemia (HeFH) is a frequent, inherited disorder of lipoprotein metabolism caused by mutations in the LDL receptor gene. The risk of CHD is approximately 50% by 5...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-002795-41 Sponsor Protocol Number: B1481038 Start Date*: 2014-02-14
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017
    Full Title: PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF M...
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Prematurely Ended) FI (Prematurely Ended) IT (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) SK (Prematurely Ended) ES (Completed) BE (Prematurely Ended) DK (Completed) SE (Completed) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002646-36 Sponsor Protocol Number: B1481022 Start Date*: 2014-02-14
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017
    Full Title: PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF M...
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) SE (Completed) SK (Prematurely Ended) ES (Completed) IT (Completed) BE (Prematurely Ended) DK (Completed) PL (Prematurely Ended) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002389-29 Sponsor Protocol Number: PULSE-COPD-007 Start Date*: 2016-07-25
    Sponsor Name:Bellerophon Pulse Technologies, LLC
    Full Title: An Exploratory Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Respiratory Imaging (FRI) Parameters in Subjects with World Health Organization (WHO) Group 3 ...
    Medical condition: Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006624-19 Sponsor Protocol Number: AVF3671g Start Date*: 2007-11-19
    Sponsor Name:Genentech, Inc.
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE IIIb TRIAL COMPARING BEVACIZUMAB THERAPY WITH OR WITHOUT ERLOTINIB AFTER COMPLETION OF CHEMOTHERAPY WITH BEVACIZUMAB FOR THE FIRST-LINE TREATM...
    Medical condition: Non-small-cell-lung-cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066490 Progression of non small cell lung cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) BG (Prematurely Ended) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-003423-21 Sponsor Protocol Number: IK-7002-COPD-006 Start Date*: 2014-09-29
    Sponsor Name:Bellerophon Pulse Technologies LLC
    Full Title: An Exploratory, Two-Part, Clinical Study to Assess the Effect of Pulsed, Inhaled Nitric Oxide (iNO) on Functional Pulmonary Imaging Parameters in Subjects with World Health Organization (WHO) Group...
    Medical condition: Part 1: Pulmonary Hypertension (PH) Associated with Chronic Obstructive Pulmonary Disease (COPD) Part 2: Pulmonary Hypertension (PH) Associated with Idiopathic pulmonary fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    18.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037401 Pulmonary hypertensions HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-000739-28 Sponsor Protocol Number: AIFA-ICSLIFE-001 Start Date*: 2018-06-26
    Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI FERRARA
    Full Title: Comparison of 1-year treatment with inhaled long acting bronchodilators (LABD) plus inhaled glucocorticosteroids (ICS) versus LABD without ICS on re-hospitalizations and/or death in elderly patient...
    Medical condition: chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005616-25 Sponsor Protocol Number: 205.342 Start Date*: 2006-07-31
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co.KG
    Full Title: A 16-week randomised, placebo-controlled, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of tiotropium inhalation solution delivered by the Respimat® inhaler (2 ...
    Medical condition: Patients with moderate persistent bronchial asthma and homozygous for arginine at the 16th position of the beta-2-adrenergic receptor
    Disease: Version SOC Term Classification Code Term Level
    9.0 10003555 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) FI (Completed) BE (Completed) DK (Completed) IT (Completed) AT (Completed) GR (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 20  21  22  23  24  25  26  27  28 
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 05 23:07:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA